iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/28725685/
G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Sep 24:1:15017.
doi: 10.1038/npjparkd.2015.17. eCollection 2015.

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease

Roger A Barker  1 , Lorenz Studer  2 , Elena Cattaneo  3 , Jun Takahashi  4 ; G-Force PD consortium
Affiliations
Editorial

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease

Roger A Barker et al. NPJ Parkinsons Dis. .

Abstract

Translating new cell-based therapies to the clinic for patients with neurodegenerative disorders is complex. It involves pre-clinical testing of the cellular product and discussions with several regulatory agencies, as well as ethical debates. In an attempt to support efforts around the world, we set up a global consortium that brings together the major funded teams working on developing a stem cell-derived neural transplantation therapy for Parkinson's disease (PD). This consortium, G-Force PD, involves teams from Europe, USA, and Japan, and has already met on two occasions to discuss common problems, solutions, and the roadmap to the clinic. In this short review, we lay out the brief history and rationale for this initiative and discuss some of the issues that arose in our most recent meeting (May 2015) as we consider undertaking first-in-human clinical trials with stem cell-derived neurons for PD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The geographical distribution of the relevant parties involved in G-Force PD. 1=NYSTEM consortium involving centers in New York and Chicago; 2=CIRM; 3=Lund University who are part of TRANSEURO and NEUROSTEMCELLREPAIR; 4=University of Milan that co-ordinates the NEUROSTEMCELLREPAIR consortium; 5=A number of UK sites including the Universities of Cambridge, Cardiff, and London who are involved in NEUROSTEMCELLREPAIR and TRANSEURO; 6=CiRA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Connolly BS , Lang AE . Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311: 1670–1683. - PubMed
    1. Jenner P . Treatment of the later stages of Parkinson's disease—pharmacological approaches now and in the future. Transl Neurodegener 2015; 4: 3. - PMC - PubMed
    1. Brundin P , Barker RA , Parmar M . Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res 2010; 184: 265–294. - PubMed
    1. Barker RA , Barrett J , Mason SL , Bjorklund A . Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 2013; 12: 84–91. - PubMed
    1. Kefalopoulou Z , Politis M , Piccini P , Mencacci N , Bhatia K , Jahanshahi M et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 2014; 71: 83–87. - PMC - PubMed

Publication types

LinkOut - more resources